Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria
Status:
Withdrawn
Trial end date:
2015-11-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the effects of 85 days treatment with MLN1202 on
urinary albumin-to-creatinine ratio (UACR) in participants with type 2 diabetes, advanced
kidney disease/diabetic nephropathy (DN) and macro-albuminuria (UACR>300 mg/g) based on
average of 3 consecutive first morning voids sample collection.